These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30556739)

  • 21. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 22. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
    Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
    Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
    Li X; Ye C; Zhang W; Jia M; Wang G
    CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.
    Pesa JA; Doshi D; Wang L; Yuce H; Baser O
    Curr Med Res Opin; 2017 Apr; 33(4):723-731. PubMed ID: 28044455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
    Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
    J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
    Martínez-Andrés JA; García-Carmona JA
    Int Clin Psychopharmacol; 2020 May; 35(3):163-169. PubMed ID: 31851035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting.
    Cirnigliaro G; Battini V; Cafaro R; Mosini G; Vanzetto S; Prodi T; Macellaro M; Leuzzi R; Conti D; Carnovale C; Dell'Osso B
    Expert Rev Neurother; 2023; 23(11):1031-1039. PubMed ID: 37750003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
    Wallman P; Clark I; Taylor D
    J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
    Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
    Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
    Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
    Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
    J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
    Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
    J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
    Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
    Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections.
    Debaveye S; De Smedt D; Heirman B; Kavanagh S; Dewulf J
    BMC Health Serv Res; 2019 Jun; 19(1):393. PubMed ID: 31217000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
    Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
    CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis.
    Patel C; Khoury AE; Huang A; Wang L; Bashyal R
    Curr Ther Res Clin Exp; 2020; 92():100587. PubMed ID: 32714469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.